Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37(9):1551–7.

Article  Google Scholar 

Ekström K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48(4):963–70.

Article  Google Scholar 

Chen Y-J, Chang Y-T, Wang C-B, Wu C-Y. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011;63(2):352–8.

Article  Google Scholar 

Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatol Oxf Engl. 2008;47(5):698–701.

CAS  Article  Google Scholar 

Parikh-Patel A, Allen M, Cress R, White RH. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009;20(6):1001–10.

Article  Google Scholar 

Lim XR, Xiang W, Tan JWL, Koh LW, Lian TY, Leong KP, et al. Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients. Int J Rheum Dis. 2019;22(9):1679–85.

Article  Google Scholar 

Askling J, Fored C, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1414–20.

CAS  Article  Google Scholar 

Simard JF, Ekberg S, Johansson ALV, Askling J. What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer? Ann Rheum Dis. 2016;75(5):862–6.

CAS  Article  Google Scholar 

Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749–59.

CAS  Article  Google Scholar 

Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res MCR. 2006;4(4):221–33.

Article  Google Scholar 

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.

Article  Google Scholar 

Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–21.

CAS  Article  Google Scholar 

Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers. 2019;11(12):2002.

CAS  Article  Google Scholar 

Wang F, Sun L, Wang S, Davis JM, Matteson EL, Murad MH, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–19.

CAS  Article  Google Scholar 

Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831–41.

Article  Google Scholar 

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

Article  Google Scholar 

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.

Article  Google Scholar 

Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet Lond Engl. 2013;381(9865):451–60.

CAS  Article  Google Scholar 

Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506–17.

CAS  Article  Google Scholar 

Fleischmann R, Pangan AL, Song I-H, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800.

CAS  Article  Google Scholar 

Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–66.

CAS  Article  Google Scholar 

Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–19.

CAS  Article  Google Scholar 

Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867–77.

CAS  Article  Google Scholar 

Li Z, Hu J, Bao C, Li X, Li X, Xu J, et al. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. Clin Exp Rheumatol. 2020;38(4):732–41.

PubMed  Google Scholar 

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheumatol. 2019;71(6):878–91.

Article  Google Scholar 

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305–19. https://doi.org/10.1002/central/CN-01981196/full.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43(3):504–11.

Article  Google Scholar 

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–62. https://doi.org/10.1056/NEJMoa1608345.

CAS  Article  PubMed  Google Scholar 

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19. https://doi.org/10.1056/NEJMoa1112072.

CAS  Article  PubMed  Google Scholar 

Westhovens R, Kavanaugh A, Jamoul C, Tasset C, Harrison P, Van Der Aa A. Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies. Ann Rheum Dis. 2017;76((Westhovens R.) Rheumatology, KU Leuven, University Hospitals, Leuven, Belgium):148. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L621422116.

Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59(6):794–9.

CAS  Article  Google Scholar 

Andersen CL, Lindegaard H, Vestergaard H, Siersma VD, Hasselbalch HC, de Fine ON, et al. Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting. PLoS ONE. 2014;9(6):e99388.

Article  Google Scholar 

Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886–95.

Article  Google Scholar 

Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212. https://doi.org/10.1186/s13075-015-0728-9.

Article  PubMed  PubMed Central  Google Scholar 

Williams CA, Bloch DA, Sibley J, Haga M, Wolfe F, Raynauld JP, et al. Lymphoma and luekemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate? J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 1996;2(2):64–72.

CAS  Google Scholar 

Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740–51. https://doi.org/10.1002/art.20311.

CAS  Article  PubMed  Google Scholar 

Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333–47.

Article  Google Scholar 

Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903–24.

CAS  Article  Google Scholar 

Comparison of malignancy and mortality rates between tofacitinib and biologic DMARDs in clinical practice: five-year results from a US-based rheumatoid arthritis registry. ACR Meeting Abstracts. https://acrabstracts.org/abstract/comparison-of-malignancy-and-mortality-rates-between-tofacitinib-and-biologic-dmards-in-clinical-practice-five-year-results-from-a-us-based-rheumatoid-arthritis-registry/. Accessed 19 Mar 2021.

Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50(5):930–7.

CAS  Article  Google Scholar 

Malignancies and serious infections in randomized controlled trials of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis. ACR Meeting Abstracts. https://acrabstracts.org/abstract/malignancies-and-serious-infections-in-randomized-controlled-trials-of-janus-kinase-inhibitors-in-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis/. Accessed 8 Jan 2021.

Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–54.

CAS  Article  Google Scholar